We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $5.98B
1-Year Est. Return 80.99%
This Fund
S&P 500
This Quarter Est. Return
+10.72%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.85B
AUM Growth
+$338M
Cap. Flow
+$79.4M
Cap. Flow %
1.36%
Top 10 Hldgs %
45.51%
Holding
707
New
76
Increased
198
Reduced
354
Closed
64

Top Buys

Rank Stock Value
1
TER icon
Teradyne
TER
+$60.1M
2
TSLA icon
Tesla
TSLA
+$32.1M
3
TSEM icon
Tower Semiconductor
TSEM
+$29.6M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$29M
5
PDD icon
Pinduoduo
PDD
+$28.1M

Top Sells

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$77.7M
2
BE icon
Bloom Energy
BE
+$53.1M
3
HOOD icon
Robinhood
HOOD
+$24.9M
4
SAP icon
SAP
SAP
+$24.1M
5
BIDU icon
Baidu
BIDU
+$21.5M

Sector Composition

Rank Sector Weight
1 Technology 51.21%
2 Communication Services 15.38%
3 Consumer Discretionary 13.01%
4 Healthcare 6.62%
5 Consumer Staples 4.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MAZE
426
Maze Therapeutics
MAZE
$1.53B
$39.1K ﹤0.01%
+944
New +$32.4K
ZYME icon
427
Zymeworks
ZYME
$1.67B
$38.7K ﹤0.01%
1,470
-147
-9% -$3.21K
OLMA icon
428
Olema Pharmaceuticals
OLMA
$1.03B
$38.6K ﹤0.01%
1,546
+69
+5% +$1.23K
IBRX icon
429
ImmunityBio
IBRX
$7.8B
$38.3K ﹤0.01%
19,355
-982
-5% -$2.23K
ZBIO
430
Zenas BioPharma
ZBIO
$2.04B
$38.3K ﹤0.01%
+1,054
New +$34.7K
TWST icon
431
Twist Bioscience
TWST
$5.69B
$38.1K ﹤0.01%
1,201
-98
-8% -$3.06K
NRIX icon
432
Nurix Therapeutics
NRIX
$2.45B
$37.8K ﹤0.01%
1,992
+347
+21% +$4.99K
TXG icon
433
10x Genomics
TXG
$6.28B
$37.3K ﹤0.01%
2,288
-173
-7% -$2.61K
KNSA icon
434
Kiniksa Pharmaceuticals
KNSA
$6.1B
$36.6K ﹤0.01%
887
-48
-5% -$1.93K
CURB
435
Curbline Properties
CURB
$3.52B
$36.5K ﹤0.01%
1,573
-8
-0.5% -$186
IVT icon
436
InvenTrust Properties
IVT
$2.74B
$36.3K ﹤0.01%
1,285
-6
-0.5% -$169
SION
437
Sionna Therapeutics
SION
$2.11B
$36K ﹤0.01%
+876
New +$33.2K
LEGN icon
438
Legend Biotech
LEGN
$3.69B
$36K ﹤0.01%
1,654
-158
-9% -$4.53K
SNDX icon
439
Syndax Pharmaceuticals
SNDX
$1.73B
$35.9K ﹤0.01%
1,708
-145
-8% -$2.53K
VCEL icon
440
Vericel Corp
VCEL
$2.43B
$35.8K ﹤0.01%
993
-93
-9% -$3.42K
STOK icon
441
Stoke Therapeutics
STOK
$1.87B
$35.6K ﹤0.01%
1,121
-58
-5% -$1.74K
HROW icon
442
Harrow
HROW
$1.45B
$35.6K ﹤0.01%
726
-70
-9% -$2.94K
DVAX
443
DELISTED
Dynavax Technologies
DVAX
$35.5K ﹤0.01%
2,306
-217
-9% -$2.39K
GMAB icon
444
Genmab
GMAB
$17.6B
$35.4K ﹤0.01%
1,148
+248
+28% +$7.73K
PHVS icon
445
Pharvaris
PHVS
$2.37B
$34.9K ﹤0.01%
+1,258
New +$30.3K
PK icon
446
Park Hotels & Resorts
PK
$3.03B
$34.8K ﹤0.01%
3,329
-17
-0.5% -$182
ANIP icon
447
ANI Pharmaceuticals
ANIP
$1.83B
$34.8K ﹤0.01%
441
-26
-6% -$2.25K
MNKD icon
448
MannKind Corp
MNKD
$1.27B
$34.2K ﹤0.01%
6,034
-567
-9% -$3.12K
NSA
449
DELISTED
National Storage Affiliates Trust
NSA
$34.1K ﹤0.01%
1,208
-15
-1% -$447
BCRX icon
450
BioCryst Pharmaceuticals
BCRX
$2.35B
$32.3K ﹤0.01%
4,137
-379
-8% -$2.74K
16 17
18
19 20

Similar funds

CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
BP
BC Partners New York $5.96B AUM 15.21% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $5.94B AUM 18.44% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
AL
Appaloosa LP Short Hills, New Jersey $5.93B AUM 44.55% 1-Year Est. Return
CGPCS
Capital Group Private Client Services Los Angeles, California $5.93B AUM 27.73% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

GF Fund Management's Q4 2025 Portfolio in Review

As of Q4 2025, GF Fund Management held 707 positions worth $5.85B, up 6.1% from $5.51B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

GF Fund Management's Q4 2025 filing shows 76 new, 198 increased, 354 reduced and 64 closed positions. Its largest new stake was Teradyne: 350,137 shares worth $67.8M. The largest sale was Broadcom, an estimated $77.7M.

By sector, the portfolio is most concentrated in Technology at 51% of assets, up from 49% a quarter earlier, followed by Communication Services and Consumer Discretionary.

  • GF Fund Management's largest Q4 2025 buy was Teradyne: 350,137 shares worth $67.8M.
  • GF Fund Management added most to Tesla in Q4 2025, an estimated $32.1M increase.
  • GF Fund Management's biggest Q4 2025 reduction was Broadcom, cutting an estimated $77.7M.
  • GF Fund Management fully exited Baidu in Q4 2025, selling an estimated $21.5M.
  • GF Fund Management's ten largest holdings make up 46% of its $5.85B portfolio in Q4 2025.
  • GF Fund Management opened 76 new positions and closed 64 in Q4 2025.
  • GF Fund Management's portfolio value rose 6.1% quarter-over-quarter to $5.85B.

Based on GF Fund Management's 13F filing for Q4 2025, filed 27 Jan 2026.